Acellular pertussis vaccine
Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 μg per human dose.
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
23.12.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 μg per human dose. |
---|---|
Bibliography: | Application Number: US201414199879 |